Current and future use of dipyridamole in patients with COVID-19
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment.
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Russo |
| Julkaistu: |
Izdatelstvo OKI
2020-10-01
|
| Sarja: | Качественная клиническая практика |
| Aiheet: | |
| Linkit: | https://www.clinvest.ru/jour/article/view/536 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|